Ī¤icagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, single-center, single blind, investigator initiated, two
period study of crossover design. Diabetic patients with Acute Coronary Syndrome (ACS),
treated with oral and/or parenteral hypoglycaemic therapy for at least 1 month and subjected
to percutaneous coronary intervention (PCI), will be randomized after a baseline platelet
reactivity (PR) assessment (24 hours post PCI) while under clopidogrel in a 1:1 ratio to
either prasugrel 10mg or ticagrelor 180mg for 15 days followed by crossover directly to the
alternate therapy for an additional 15 days without an intervening washout period.